STOCK TITAN

Kezar Life Sciences - KZR STOCK NEWS

Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.

Kezar Life Sciences (KZR) is a clinical-stage biotechnology company pioneering novel small molecule therapeutics for autoimmune disorders and oncology. This page provides authoritative updates on corporate developments, clinical research, and strategic initiatives essential for informed decision-making.

Access real-time updates on KZR-616 clinical trials, regulatory milestones, and scientific advancements alongside financial disclosures and partnership announcements. Our curated news collection serves investors, researchers, and healthcare professionals seeking comprehensive insights into the company’s progress.

Key coverage areas include immunoproteasome inhibitor developments, trial phase updates, intellectual property news, and collaborative research efforts. All content undergoes rigorous verification to ensure alignment with SEC filings and peer-reviewed publications.

Bookmark this page for streamlined access to KZR’s latest material events. Combine our news monitoring with SEC filings and medical journals for complete due diligence.

Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotech firm focusing on novel small molecule therapeutics for immune-mediated diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 11, 2024, at 12:00 pm ET in New York, NY.

Chris Kirk, Co-founder and CEO of Kezar, will deliver a corporate overview during the presentation. Investors and interested parties can access a live webcast of the presentation through the "Events & Presentations" section on Kezar's official website. An archived version of the webcast will remain available on the site for 90 days following the event, providing extended access to the company's latest updates and strategic outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
conferences
-
Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. Completed enrollment in PORTOLA Phase 2a trial of zetomipzomib for autoimmune hepatitis; topline data expected in H1 2025.

2. PALIZADE Phase 2b trial of zetomipzomib for lupus nephritis ongoing; topline data expected mid-2026.

3. Stopped enrollment in KZR-261 Phase 1 study for solid tumors; focusing resources on zetomipzomib programs.

4. Cash, cash equivalents, and marketable securities totaled $164.2 million as of June 30, 2024.

5. Q2 2024 net loss of $21.5 million ($0.30 per share) compared to $24.3 million ($0.34 per share) in Q2 2023.

6. R&D expenses decreased to $16.3 million from $21.0 million in Q2 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
-
Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR) has announced the granting of a nonqualified stock option to a new employee as an inducement award under Nasdaq Listing Rule 5635(c)(4). The option allows the purchase of 72,000 shares at $0.55 per share, matching the closing price on July 8, 2024. The award aims to attract the individual to join Kezar. The stock options will vest over four years: 25% on the first anniversary of the employee’s start date, and 1/48th monthly thereafter, conditional on continued employment. The grant is governed by Kezar’s 2022 Inducement Plan and specific stock option agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.53%
Tags
none
Rhea-AI Summary

Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotech firm, announced a nonqualified stock option grant to purchase 80,000 shares at $0.71 per share.

The stock option, granted to a new employee on June 3, 2024, is in line with Nasdaq Listing Rule 5635(c)(4). The grant is part of Kezar's strategy to attract top talent.

The options will vest over four years: 25% after the first year, with the remainder vesting monthly. This grant is material to the individual’s employment agreement and is part of Kezar's 2022 Inducement Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Summary

Kezar Life Sciences, a clinical-stage biotechnology company listed on Nasdaq (KZR), announced that its CEO, Chris Kirk, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 12:30 pm ET in New York. The company focuses on developing novel small molecule therapeutics for immune-mediated diseases and cancer. The event will be webcasted live and available on Kezar's website for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
conferences
-
Rhea-AI Summary

Kezar Life Sciences, Inc. reported its first quarter 2024 financial results and business update, including progress in clinical trials for zetomipzomib in lupus nephritis and autoimmune hepatitis, and dose expansion for KZR-261 in melanoma. Cash, cash equivalents, and marketable securities totaled $179.8 million. R&D expenses decreased to $17.2 million, while G&A expenses increased to $6.5 million. Net loss was $21.7 million for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
Rhea-AI Summary

Kezar Life Sciences, Inc. granted two employees nonqualified stock options to purchase 164,000 shares of common stock at $0.84 per share under NASDAQ Listing Rule 5635(c)(4). The options will vest over four years, with 25% on the first anniversary and 1/48th monthly thereafter, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
-
Rhea-AI Summary
Kezar Life Sciences, Inc. granted an employee a nonqualified stock option to purchase 12,000 shares at $0.93 per share, vesting over four years. The option was given as an inducement award for joining the company, following Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
-
Rhea-AI Summary
Kezar Life Sciences, Inc. (KZR) provided a business update, highlighting the progress of their zetomipzomib programs for autoimmune disorders. The PALIZADE Phase 2b trial for lupus nephritis and PORTOLA Phase 2a trial for autoimmune hepatitis are actively enrolling with topline data expected in 2025 and 2026. The KZR-261 dose escalation study is ongoing with a data update by year-end. Financially, the company reported $201.4 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
Rhea-AI Summary
Kezar Life Sciences, Inc. granted an employee a nonqualified stock option to purchase 36,000 shares at $1.03 per share, vesting over four years. This award aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Kezar Life Sciences

Nasdaq:KZR

KZR Rankings

KZR Stock Data

30.39M
6.23M
12%
62%
0.64%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO